pAAV-RSV-SpCas9 Citations (4)
Originally described in: The CRISPR/Cas9-created MDM2 T309G enhances vitreous-induced expression of MDM2 and proliferation and survival of cells.Duan Y, Ma G, Huang X, D'Amore PA, Zhang F, Lei H J Biol Chem. 2016 May 31. pii: jbc.M116.729467. PubMed Journal
Articles Citing pAAV-RSV-SpCas9
| Articles |
|---|
| Synthetic immunomodulation with a CRISPR super-repressor in vivo. Moghadam F, LeGraw R, Velazquez JJ, Yeo NC, Xu C, Park J, Chavez A, Ebrahimkhani MR, Kiani S. Nat Cell Biol. 2020 Sep;22(9):1143-1154. doi: 10.1038/s41556-020-0563-3. Epub 2020 Sep 3. PubMed |
| AAV-mediated in vivo genome editing in vascular endothelial cells. Wu W, Yang Y, Yao F, Dong L, Xia X, Zhang S, Lei H. Methods. 2020 Dec 9. pii: S1046-2023(20)30263-2. doi: 10.1016/j.ymeth.2020.12.001. PubMed |
An AAV-CRISPR/Cas9 strategy for gene editing across divergent rodent species: Targeting neural oxytocin receptors as a proof of concept.
Boender AJ, Boon M, Albers HE, Eck SR, Fricker BA, Kelly AM, LeDoux JE, Motta SC, Shrestha P, Taylor JH, Trainor BC, Triana-Del Rio R, Young LJ.
Sci Adv. 2023 Jun 2;9(22):eadf4950. doi: 10.1126/sciadv.adf4950. Epub 2023 May 31.
PubMed
Associated Plasmids |
| Leverage of nuclease-deficient CasX for preventing pathological angiogenesis. Han H, Yang Y, Jiao Y, Qi H, Han Z, Wang L, Dong L, Tian J, Vanhaesebroeck B, Li X, Liu J, Ma G, Lei H. Mol Ther Nucleic Acids. 2023 Aug 6;33:738-748. doi: 10.1016/j.omtn.2023.08.001. eCollection 2023 Sep 12. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.